HC Wainwright Reaffirms “Buy” Rating for Homology Medicines (NASDAQ:FIXX)

HC Wainwright restated their buy rating on shares of Homology Medicines (NASDAQ:FIXXGet Rating) in a research note published on Tuesday morning, PriceTargets.com reports. HC Wainwright also issued estimates for Homology Medicines’ Q4 2022 earnings at ($0.57) EPS, FY2022 earnings at ($1.86) EPS, Q1 2023 earnings at ($0.56) EPS, Q2 2023 earnings at ($0.56) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.56) EPS, FY2023 earnings at ($2.24) EPS, FY2024 earnings at ($1.24) EPS, FY2025 earnings at ($0.39) EPS and FY2026 earnings at $0.28 EPS.

A number of other equities research analysts have also weighed in on FIXX. BTIG Research lowered their price objective on shares of Homology Medicines from $29.00 to $12.00 and set a buy rating for the company in a report on Tuesday, August 16th. Robert W. Baird decreased their price objective on Homology Medicines from $10.00 to $9.00 and set an outperform rating on the stock in a report on Wednesday, August 31st. Royal Bank of Canada lowered their target price on Homology Medicines from $4.00 to $3.00 and set a sector perform rating for the company in a research note on Friday, November 11th. Chardan Capital reduced their price target on Homology Medicines from $10.00 to $8.00 and set a buy rating on the stock in a research report on Thursday, November 17th. Finally, Credit Suisse Group decreased their price target on Homology Medicines to $2.10 in a research note on Wednesday, November 16th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Homology Medicines has a consensus rating of Moderate Buy and an average target price of $8.57.

Homology Medicines Trading Down 10.0 %

Shares of NASDAQ FIXX opened at $1.62 on Tuesday. The stock’s 50-day moving average is $1.56 and its 200 day moving average is $1.93. The stock has a market cap of $93.12 million, a price-to-earnings ratio of -16.20 and a beta of -0.19. Homology Medicines has a 1-year low of $1.30 and a 1-year high of $5.34.

Hedge Funds Weigh In On Homology Medicines

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP boosted its holdings in Homology Medicines by 40.4% in the third quarter. Marshall Wace LLP now owns 30,175 shares of the company’s stock valued at $48,000 after acquiring an additional 8,689 shares in the last quarter. Arizona State Retirement System purchased a new stake in shares of Homology Medicines in the 1st quarter worth about $31,000. Renaissance Technologies LLC boosted its stake in shares of Homology Medicines by 6.3% during the 2nd quarter. Renaissance Technologies LLC now owns 248,800 shares of the company’s stock valued at $490,000 after purchasing an additional 14,800 shares in the last quarter. Raymond James & Associates bought a new stake in shares of Homology Medicines during the 1st quarter valued at about $51,000. Finally, Mirabella Financial Services LLP purchased a new position in shares of Homology Medicines during the first quarter valued at about $53,000. 43.20% of the stock is owned by hedge funds and other institutional investors.

Homology Medicines Company Profile

(Get Rating)

Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.

Recommended Stories

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.